Results 31 to 40 of about 30,804 (255)

Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction

Redox Biology, 2016
Proton pump inhibitors (PPIs) are widely used drugs that may increase the cardiovascular risk by mechanisms not entirely known. While PPIs increase asymmetric dimethylarginine (ADMA) levels and inhibit nitric oxide production, it is unknown whether ...
Lucas C. Pinheiro, Gustavo H. Oliveira-Paula, Rafael L. Portella, Danielle A. Guimarães, Celio D. de Angelis, Jose E. Tanus-Santos   +5 more
doaj   +1 more source

Antioxidant protection enzyme activity in the blood serum and large intestinal mucosa of rats with prolonged gastric hypochlorhydria and given multiprobiotics

Regulatory Mechanisms in Biosystems, 2019
The activity of antioxidant protection enzymes in the blood serum and colon mucosa in rats was studied under the conditions of 28-days administration of omeprazole on its own and omeprazole together with multiprobiotics "Symbiter" and "Apibact ...
S. V. Pylypenko, A. A. Koval
doaj   +1 more source

Evaluation of the effects of medium‐term (57‐day) omeprazole administration and of omeprazole discontinuation on serum gastrin and serum chromogranin A concentrations in the horse

Journal of Veterinary Internal Medicine, 2023
Background Rebound gastric hyperacidity (RGH) secondary to hypergastrinemia has been suggested to contribute to the rapid recurrence of equine squamous gastric disease (ESGD) in horses after discontinuation of omeprazole.
Bethanie Clark, Catherine Steel, Jessica Vokes, Jack R. Shan, Kristene Gedye, Amy Lovett, B. W. Sykes   +6 more
doaj   +1 more source

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry [PDF]

, 2015
Emerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs.
Temperton, Nigel J., Molesti, E, Barclay, W., Barclay, W, Wendy Barclay (686216), Eleonora Molesti, Nigel Temperton (5830610), Temperton, N, Barclay, Wendy, Edward Wright, Long, J., Molesti, E., Edward Wright (4468198), Molesti, Eleonora, Temperton, N., Long, Jason, Wright, E, Jason Long (40805), Wendy Barclay, Eleonora Molesti (686215), Wright, Edward, Wright, E., Nigel Temperton, Long, J, Jason Long   +24 more
core   +1 more source

Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics

, 2022
INTRODUCTION: The prevalence of obesity is increasing globally. The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability and pharmacokinetic (PK) parameters of omeprazole.
Rubio, Miguel A., Bandrés Moya, Fernando, López Picado, Amanda, Vargas Castrillon, Emilio, Rivas Paterna, Ana Belen, Chicharro, Luis M., López-Picado, Amanda, Portolés-Pérez, Antonio, Paterna, Ana Belén Rivas, Sánchez Pernaute, Andrés, Bandrés, Fernando, Moreno Lopera, Carmen, Castrillón, Emilio Vargas, Portolés Pérez, Antonio, Torres García, Antonio José   +14 more
core   +1 more source

Molecular mechanism of inhibition of the mitochondrial carnitine/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. [PDF]

PLoS ONE, 2013
The effect of omeprazole on the mitochondrial carnitine/acylcarnitine transporter has been studied in proteoliposomes. Externally added omeprazole inhibited the carnitine/carnitine antiport catalysed by the transporter.
Annamaria Tonazzi, Ivano Eberini, Cesare Indiveri   +2 more
doaj   +1 more source

Cu(II), Zn(II), Cd(II) and Hg(II) Complexes of Omeprazole (PPZH): Synthesis and Characterization

, 2023
Omeprazole is a widely used proton pump inhibitor. This is used for the treatment of gasteo-oesophageal reflux diseases as well as acid induced inflammation disorders of the stomach and duodenum. In the scheme of gradual release and extended acting drugs,
Md Motiur, Mazumder, Salma , Begum, Humaira, Yeasmin, Md , Akteruzzaman   +3 more
core   +1 more source

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats

Pharmaceutical Biology, 2019
Context: Omeprazole and astragaloside IV (AS-IV) are widely used for the treatment of gastric ulcers in China clinics. Objective: This study investigates the effects of AS-IV on the pharmacokinetics of omeprazole in rats.
Wei Liu, Guozhi Liu, Jing Liu
doaj   +1 more source

Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: Faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1

Journal of Pharmacy & Pharmaceutical Sciences, 2007
Purpose. To investigate the effect of diabetes mellitus induced by alloxan (DMIA) or streptozotocin (DMIS) on the pharmacokinetics of omeprazole in rats.
Dae Young Lee, Myung G. Lee, Hyun Sook Shin, Inchul Lee   +3 more
doaj   +1 more source

Impact of fresh grape juice on the pharmacokinetics of omeprazole: results of a food–drug interaction study

Frontiers in Pharmacology
Grapes have been widely used for dietary ailments due to their attributed pharmacological activities. Resveratrol, the chief constituent of grapes, is responsible for their pharmacological benefits.
Tayyaba Iftikhar, Zafar Iqbal, Yasar Shah, Nauman Rahim Khan, Muhammad Abbas, Omer Shehzad, Fazal Hadi, Haseeba Sardar, Ali Abusharha, Maria Daglia, Maria Daglia, Haroon Khan, Haroon Khan   +12 more
doaj   +1 more source